139911-30-1

Basic information

• Product Name: Ethyl 2-chloro-5-fluoronicotinate
• Synonyms: 2-CHLORO-5-FLUORONICOTINIC ACID ETHYL ESTER;Ethyl2-Chloro-5-fluoronicotinicacid;2-CHLORO-5-FLUORONICOTONIC ACID ETHYL ESTER;Ethyl 2-chloro-5-fluoronicotinate;2-CHLORO-5-FLUORONICOTINI...;ethyl 2-chloro-5-fluoropyridine-3-carboxylate;Ethyl 2-chloro-5-fluoropyridine-3-carboxylate, 2-Chloro-3-(ethoxycarbonyl)-5-fluoropyridine;ethyl 2-chloro-5-fluoropyridin-3-carboxylate
• CAS NO: 139911-30-1
• Molecular Formula: C₈H₇ClFNO₂
• Molecular Weight: 203.6
• Product Categories: Pyridine;pharmacetical;Pyridines
• Mol File: 139911-30-1.mol

Chemical Properties

• Boiling Point: 252.654 °C at 760 mmHg
• Flash Point: 106.602 °C
• Appearance: /
• Density: 1.329 g/cm³
• Vapor Pressure: 0.0191mmHg at 25°C
• Refractive Index: 1.507
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Ethyl 2-chloro-5-fluoronicotinate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 2-chloro-5-fluoronicotinate(139911-30-1)
• EPA Substance Registry System: Ethyl 2-chloro-5-fluoronicotinate(139911-30-1)

Safety Data

• Hazardous Substances Data: 139911-30-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 2-chloro-5-fluoronicotinate is used as a key intermediate in the synthesis of pharmaceutical compounds for its potential therapeutic benefits. Its role in drug development is crucial, as it aids in the creation of medications that can address a range of health conditions.
It is important to handle Ethyl 2-chloro-5-fluoronicotinate with care, as it may pose health hazards if not used properly. Proper safety measures should be taken during its production, storage, and application to ensure the well-being of those involved in its use.

InChI:InChI=1/C8H7ClFNO2/c1-2-13-8(12)6-3-5(10)4-11-7(6)9/h3-4H,2H2,1H3

Upstream product

• 151322-65-5 ethyl 2-chloro-5-fluoro-6-(methylthio)pyridine-3-carboxylate 
• 82671-03-2 ethyl 2,6-dichloro-5-fluoropyridine-3-carboxylate 
• 64-17-5 ethanol 
• 38186-88-8 2-chloro-5-fluoronicotinic acid 
• 1316084-72-6 (2E,4Z)-ethyl 2-cyano-5-(dimethylamino)-4-fluoro-penta-2,4-dienoate 
• 82671-06-5 2,6-dichloro-5-fluoro-3-pyridinecarboxylic acid 

Downstream Products

• 948915-40-0 Ethyl 2-({[4-(1,1-dimethylethyl)phenyl]methyl}amino)-5-fluoro-3-pyridinecarboxylate 
• 884494-33-1 2-chloro-5-fluoro-3-iodo-pyridine 
• 791644-48-9 2-chloro-5-fluoronicotinonitrile 
• 1316084-69-1 C₁₄H₁₀F₃NO₃ 
• 1239355-71-5 C₁₂H₆Cl₂FNO₃ 
• 1239355-72-6 C₁₂H₇ClFNO₃ 
• 1239354-65-4 2-[(2,4-dichlorophenyl)oxy]-5-fluoro-N-[(1R)-2-(4-methylpiperazin-1-yl)-2-oxo-1-{[(phenylmethyl)oxy]methyl}ethyl]pyridine-3-carboxamide 
• 1239354-63-2 2-[(4-chlorophenyl)oxy]-5-fluoro-N-[(1R)-2-(4-methylpiperazin-1-yl)-2-oxo-1-{[(phenylmethyl)oxy]methyl}ethyl]pyridine-3-carboxamide 
• 139911-21-0 ethyl 2-(2-methyl-4-fluorophenyl)-5-fluoro-3-pyridinecarboxylate 
• 837377-30-7 5-fluoro-2-(3-ethylsulfanyl-phenoxy)-nicotinic acid ethyl ester 
• 837377-33-0 5-fluoro-2-(4-methylsulfanyl-phenoxy)-nicotinic acid ethyl ester 
• 832099-54-4 5-fluoro-2-(3-methylsulphanyl-phenoxy)-nicotinic acid ethyl ester 
• 38186-88-8 2-chloro-5-fluoronicotinic acid 
• 582333-25-3 2-(3,4-dichloro-phenoxy)-5-fluoro-nicotinic acid ethyl ester 

Relevant articles and documents

A modified approach to C-14-labeled 2-(3,4-difluorophenoxy)-5- fluoronicotinic acid and other halogen-substituted analogs

A modified approach to a carbon-14-labeled pyridine ring system was developed based on the electrocyclic ring-closure of 1,4,4-trisubstituted butadiene. The new method was applied to prepare 2-(3,4-difluorophenoxy)-5- fluoro-[2-14C] nicotinic a

Non-nucleoside inhibitors of HCV NS5B polymerase. Part 1: Synthetic and computational exploration of the binding modes of benzothiadiazine and 1,4-benzothiazine HCV NS5b polymerase inhibitors

The importance of internal hydrogen bonding in a series of benzothiadiazine and 1,4-benzothiazine NS5b inhibitors has been explored. Computational analysis has been used to compare the protonated vs. anionic forms of each series and we demonstrate that activity against HCV NS5b polymerase is best explained using the anionic forms. The syntheses and structure-activity relationships for a variety of new analogs are also discussed.

Method for producing 3-substituted 2-chloro-5-fluoro-pyridine or its salt

To provide a method for producing a 3-substituted 2-chloro-5-fluoro-pyridine or its salt in high yield from a readily available material through a short process under mild reaction conditions using a reagent which is easy for handling and simple in the reaction operation. Namely, a method for producing the following compound (2) or its salt which comprises selectively reducing a chlorine atom at the 6-position of the following compound (1) or its salt, is provided. Further, a method for producing the following compound (4) or its salt which comprises substituting a Z1 group of the following compound (2) or its salt obtained by the reduction reaction, by a Z2 group, is provided. Here, Z1 is —CO2R1, etc., and R1 is a hydrogen atom, an alkyl group, an alkenyl group, an aryl group, an aralkyl group or a cycloalkyl group. Z2 is a group different from Z1 and is —CO2R5, etc., and R5 is an alkyl group, an alkenyl group, an aryl group, an aralkyl group or a cycloalkyl group.

Nicotinamide derivatives useful as PDE4 inhibitors

This invention relates to nicotinamide derivatives of general formula (I): in which R1, R2 and R3 have the meanings defined herein, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of such derivatives.

Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes

Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, of the formula: wherein j is 0 or 1, k is 0 or 1, m is 0, 1, or 2;n is 1 or 2; A is is selected from the partial Formulas: where q is 1, 2, or 3, W3 is -O-; -N(R9)-; or -OC(=O)-; R7 is selected from -H; -(C1-C6)alkyl, -(C2-C6)alkenyl, or -(C2-C6)alkynyl substituted by 0 to 3 substituents R10; -(CH2)u-(C3-C7) cycloalkyl where u is 0, 1 or 2, substituted by 0 to 3 R10; and phenyl or benzyl substituted by 0 to 3 R14; R8 is tetrazol-5-yl; 1,2,4-triazol-3-yl; 1,2,4-triazol-3-on-5-yl; 1,2,3-triazol-5-yl; imidazol-2-yl; imidazol-4-yl; imidazolidin-2-on-4-yl; 1,3,4-oxadiazolyl; 1,3,4-oxadiazol-2-on-5-yl; 1,2,4-oxadiazol-3-yl; 1,2,4-oxadiazol-5-on-3-yl; 1,2,4-oxadiazol-5-yl; 1,2,4-oxadiazol-3-on-5-yl; 1,2,5-thiadiazolyl; 1,3,4-thiadiazolyl; morpholinyl; parathiazinyl; oxazolyl; isoxazolyl; thiazolyl; isothiazolyl; pyrrolyl; pyrazolyl; succinimidyl; glutarimidyl; pyrrolidonyl; 2-piperidonyl; 2-pyridonyl; 4-pyridonyl; pyridazin-3-onyl; pyridyl; pyrimidinyl; pyrazinyl; pyridazinyl; indolyl; indolinyl; isoindolinyl; benzo[b]furanyl; 2,3-dihydrobenzofuranyl; 1,3-dihydroisobenzofuranyl; 2H-1-benzopyranyl; 2-H-chromenyl; chromanyl; benzothienyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; benzisoxazolyl; benzothiazolyl; benzotriazolyl; benzotriazinyl; phthalazinyl; 1,8-naphthyridinyl; quinolinyl; isoquinolinyl; quinazolinyl; quinoxalinyl; pyrazolo[3,4-d]pyrimidinyl; pyrimido[4,5-d]pyrimidinyl; imidazo[1,2-a]pyridinyl; pyridopyridinyl; pteridinyl; or 1H-purinyl; or A is selected from phosphorous and sulfur acid groups; W is ―O―; ―S(=O)t―, where t is 0, 1, or 2; or -N(R3)―; Y is C(R1a)―, or -[N□(O)k] where k is 0 or 1; R4, R5 and R6 are (1)―H; provided that R5 and R6 are not both -H at the same time, ―F; ―Cl; -(C2-C4) alkynyl; -R16; ―OR16; -S(=O)pR16; ―C(=O)R16, -C(=O)OR16; -OC(=O)R16; -CN; -NO2; -C(=O)NR16R17; -OC(=O)NR16R17; ―NR12aC(=O)NR16R17; -NR12aC(=NR12)NR16R17; -NR12aC(=NCN)NR15R16; -NR12aC(=N-NO2)NR15R16; -C(=NR12a)NR15R16; -CH2C(=NR12a)NR16R17; ―OC(=NR12a)NR16R17; ―OC(=N―NO2)NR16R17; -NR16R17; -CH2NR16R17; -NR12aC(=O)R16; -NR12aC(=O)OR16; =NOR16; ―NR12aS(=O)pR17 -S(=O)pNR16R17; and ―CH2C(=NR12a)NR16R17;(2) -(C1-C4) alkyl including dimethyl and -(C1-C4) alkoxy substituted with 0 to 3 substituents ―F or ―Cl; or 0 or 1 substituent (C1-C2) alkoxycarbonyl―, (C1-C2) alkylcarbonyl―, or (C1-C2) alkylcarbonyloxy―; or (3) an aryl or heterocyclic moiety; or (4) R5 and R6 are taken together to form a moiety of partial Formulas (1.3.1) through (1.3.15):B1 and B2 is a moiety comprising a saturated or unsaturated carbon ring system that is 3- to 7-membered monocyclic, or that is 7- to 12-membered, fused or discontinuous, polycyclic; wherein optionally one carbon atom thereof may be replaced by a heteroatom selected from N, O and S; and where N is selected, optionally a second carbon atom thereof may be replaced by a heteroatom selected from N, O, or S; or a pharmaceutically acceptable salt thereof.

Angiotensin II receptor antagonists

Compounds are disclosed having the formula: STR1 The compounds of the invention are angiotensin II receptor antagonists.

2-(Alkylamino)nicotinic Acid and Analogs. Potent Angiotensin II Antagonists

A series of pyridines and other six-membered ring heterocycles connected to a biphenyltetrazole with a-CH2-NR'-link (1) were discovered to be potent angiotensin II antagonists.In the pyrimidine carboxylic acid series (W = CR, X = N, Y = CH, Z = COOH), compounds with an alkyl group (R') on the exocyclic nitrogen were much more potent than compounds with an alkyl group (R) on the heterocyclic ring.The corresponding pyridine, pyridazine, pyrazine, and 1,2,4-triazine carboxylic acids also showed potent in vitro angiotensin II antagonism.The pyridine (W, X, Y = CH, Z = COOH, R' = n-C3H7) demonstrated potent in vitro activity (pA2 = 10.10, rabbit aorta, and Ki = 0.61 nM, receptor binding in rat liver) as well as exceptional oral antihypertensive activity and bioavailability.Any nonacidic replacement for the carboxylic acid was detrimental for activity.